Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 9. Correlation between ATRX expression, TILs level and survival outcomes in patients with on the TMA. (A) Correlation between ATRX and OS, DFS in the four BC subtypes. (B) Correlation between ATRX combined with TILs and OS, DFS in the four BC subtypes. (C) Correlation between ATRX (or ATRX combining with TILs) and OS, DFS in patients with BC. ATRX(H): ATRX-High expression group, ATRX(L): ATRX-Low expression group, Opposite: the group with ATRX expression tendency opposited to TILs, both H: both ATRX- and TILs-High group, both L: both ATRX- and TILs-Low group.